News & Updates

UDCA-induced GLOBE score changes tied to survival in primary biliary cholangitis
UDCA-induced GLOBE score changes tied to survival in primary biliary cholangitis
04 Aug 2023

In patients with primary biliary cholangitis (PBC), changes in the GLOBE score (ΔGLOBE) brought about by treatment with ursodeoxycholic acid (UDCA) are predictive of liver transplantation (LT)-free survival, reports a study.

UDCA-induced GLOBE score changes tied to survival in primary biliary cholangitis
04 Aug 2023
Head-to-head trial STAMPs asciminib mark in CML treatment landscape
Head-to-head trial STAMPs asciminib mark in CML treatment landscape
04 Aug 2023 byAudrey Abella

In the exploratory analyses of the phase III ASCEMBL trial, individuals with chronic myeloid leukaemia in chronic phase (CML-CP) who have failed ≥2 prior tyrosine kinase inhibitors (TKIs) continued to achieve deep responses with asciminib, the first BCR::ABL1 inhibitor to Specifically Target the ABL Myristoyl Pocket (STAMP).

Head-to-head trial STAMPs asciminib mark in CML treatment landscape
04 Aug 2023
Memories of childhood maltreatment affect mental health more than the abuse itself
Memories of childhood maltreatment affect mental health more than the abuse itself
04 Aug 2023
HDP exposure in gestation, maternal hypertension spell increased hypertension risk in offspring
HDP exposure in gestation, maternal hypertension spell increased hypertension risk in offspring
03 Aug 2023

Exposure to hypertensive disorders of pregnancy (HDP) in gestation and maternal hypertension both contribute to an elevated risk of chronic hypertension in offspring, as reported in a study.

HDP exposure in gestation, maternal hypertension spell increased hypertension risk in offspring
03 Aug 2023
Hybrid, bismuth quadruple therapies superior to high-dose dual therapy for H pylori eradication
Hybrid, bismuth quadruple therapies superior to high-dose dual therapy for H pylori eradication
03 Aug 2023

In the first-line treatment of Helicobacter pylori (H pylori) infection, 14-day hybrid therapy and 10-day bismuth quadruple therapy demonstrate superiority over 14-day high-dose dual therapy, reports a Taiwan study. However, high-dose therapy results in fewer adverse events than hybrid bismuth quadruple therapies.

Hybrid, bismuth quadruple therapies superior to high-dose dual therapy for H pylori eradication
03 Aug 2023
Synbiotics help reduce weight in adults with overweight, obesity
Synbiotics help reduce weight in adults with overweight, obesity
03 Aug 2023